News & Events: Hope Act

Researcher of the Month: Peter Stock, MD, PhD As a pivotal figure in HIV-to-HIV organ transplantation and its legalization through the passage of the HIV Organ Policy Equity (HOPE) Act, transplant surgeon Peter G. Stock, MD., PhD., continues to strive toward breakthroughs in research. While Stock is mostly known for his HIV transplantation work, he has been investigating pancreatic islet transplantation (also known as beta cell replacement) to cure type 1 diabetes since his days as a PhD student at the University of Minnesota. In May, the California Institute for Regenerative Medicine [...]

President Barack Obama signs the HOPE Act legislation in November 2013. Peter Stock (far left) had earlier testified before Congress in support of the legislation, which overturned a federal ban on HIV-to-HIV transplants. Photo by Evan Vucci UCSF News reports on the epic battle, led by UCSF transplant surgeon Peter G. Stock, M.D., Ph.D., to repeal long-standing federal and state laws banning HIV-to-HIV organ transplantation, this after having served as lead Principal Investigator on a landmark clinical trial demonstrating the feasibility and clinical benefit of such transplants, and, in [...]

President Barack Obama signs S. 330: HIV Organ Policy Equity Act during a signing ceremony in the Oval Office, Nov. 21, 2013. (Official White House Photo by Lawrence Jackson) MSNBC reports on President Obama's signing of  a bill that ended a decades-old policy that banned organ donations from one HIV-positive person to another. A clinical trial led by UCSF transplant surgeon Peter G. Stock, M.D., Ph.D. was instrumental to the passage of the Hope Act that lifted the ban. The HIV Organ Policy Equity (HOPE) Act allows organ transplants between HIV-infected individuals for medical research [...]

Last year, a team led by Dr. Peter Stock of UCSF reported on results from a large multicenter study testing the safety and feasibility of transplanting kidneys where both the donor and recipients were infected with HIV, the virus that causes AIDS. The results, reported in the New England Journal of Medicine, showed that the recipients survived nearly as long as non-HIV infected recipients of kidney transplants. As a result of the Stock-led trial, and a just-published paper from Johns Hopkins projecting that 500 to 600 H.I.V.-infected livers and kidneys would become available each year if the [...]